Immunotherapy after surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of esophageal cancer called squamous cell carcinoma.
- You must have received a combination of chemotherapy, immunotherapy, and a taxane drug (a kind of chemotherapy) before surgery.
- You must have had surgery to completely remove the cancer, and the surgeon confirmed clear margins (R0).
- After surgery, tests must show some cancer remaining in the removed tissue or lymph nodes (stage ypT1 or higher, or ypN1 or higher).
- You must be generally healthy enough to receive the study treatment, with an ECOG performance status of 0 or 1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study looks back at patients who received immunotherapy and chemotherapy before surgery for esophageal cancer, to see how often the cancer comes back after surgery. It may help doctors understand which patients benefit the most from this treatment approach.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
This trial tests a new combination of immunotherapy (toripalimab) with two chemotherapy drugs before surgery for esophageal cancer, compared to a standard chemo regimen. The goal is to see if the new combination improves outcomes for patients with resectable tumors.
This trial tests whether continuing immunotherapy (toripalimab) after surgery helps prevent esophageal cancer from coming back. It is for people who already had surgery for squamous cell esophageal cancer after receiving immunotherapy plus chemotherapy before surgery.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can shrink esophageal cancer and improve outcomes. It is designed for patients with early-stage but treatable esophageal squamous cell carcinoma who are candidates for surgery.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.